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ABsTRACT
the objectives of new topical formulations for the treatment of glaucoma are to reduce the intraocular 
pressure (IOP) and minimize the occurrence of side effects. the aim of this study was to determine the effects 
of topical application of timolol maleate gel formulation 0.1% applied once daily, on the intraocular pressure 
and pulse rate (Pr) in ten healthy dogs. a clinical blinded trial was performed over two different periods; 
each period was divided into a pretreatment phase (D0) and four days of treatment (D1-4), with a wash out 
period of 10 days. treatments consisted of administration of one drop of timolol 0.1% gel formulation once a 
day and artificial tears. The IOP and PR values were recorded in all animals five times daily (7:00 AM, 10:00 
AM, 1:00 PM, 5:00 PM, and 9:00 PM). Adverse events (conjunctival hyperemia, discomfort, breathing, and 
allergic reaction) were documented. Compared with the placebo treatment, the topical treatment with timolol 
gel formulation resulted in a significant decrease in IOP and PR. Already 24 hours after administration, TMG 
induced a significant reduction in IOP. In the group treated with TMG the mean decrease in IOP was 3.4 mm 
hg (P<0.01), the mean decrease in Pr was 10.8 (P<0.01). topical administration of timolol maleate gel 0.1% 
formula was effective in lowering IOP in healthy dogs. the gel formulation improves bioavailability, but it 
seems there was no reduction in adverse cardiopulmonary effects. 
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introduction 
Glaucoma is actually considered to be a group of diseases, associated with retinal 
ganglion cell (RGC) death (OSBORNE et al., 2016). The principal risk factor related 
to glaucoma is the elevation of intraocular pressure (IOP), resulting in loss of vision by 
destruction of ocular structures. So, the treatment mainly aims at reducing intraocular 
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pressure, in order to maintain the integrity of the optic nerve. Beta adrenergic antagonists 
such as timolol are ocular hypotensive agents, widely used for treatment of glaucoma in 
humans and dogs, and they decrease the production of aqueous humor (REALINI, 2011; 
CONLON et al., 2017). In general the side effects are reported of beta-blockers in the 
eye drops on the cardiovascular and respiratory systems (MAENPAA and PELKONEN, 
2016). 
In order to overcome the limitations related to the administration of eye drops, recent 
studies have developed a new formulation of timolol maleate in gel form, which should 
ensure the better permeability of the drug. the new formulation in gel form should prolong 
the residence time in the precorneal region, thereby increasing its therapeutic effects. 
this study aimed to determine the potential therapeutic effects of timolol maleate gel 
formulation 0.1% on reducing intraocular pressure and to monitor the side effects on the 
cardiovascular system in healthy dogs.
Materials and methods
Animals. A total of 10 owned and healthy, mixed-breed dogs (3 intact males, 7 intact 
females), between 12 and 18 months old (median age 14 months; SD 2.26), weighing 6-9 
Kg (median weight: 7 kg) were included in the study. The dogs’ main characteristics are 
summarized in Table 1. All subjects were defined as healthy after a complete physical 
examination and an electrocardiogram, including a record of heart rate. None of dogs had 
signs of ocular disease, as determined by complete ophthalmic examination, including 
a Schirmer tear test (STT), fluorescein staining, slit-lamp biomicroscopy, applanation 
tonometry, gonioscopy and dilated fundus examination. 
Table 1. Dogs’ main characteristics
total 10
age (median) 14 months
Male (%) 30
Female (%) 70
Weigh (median)   7 kg
This study was carried in accordance with the ethical principles of the Veterinarians’ 
ethical Code (PaSSaNtINO, 2007) - with respect to the high standard of veterinary care 
and veterinary best practice - and the Italian and european regulations on animal welfare 
(Directive 2010/63/EU of the European Parliament and of the Council of 22 September 
2010 on the protection of animals used for scientific purposes.). 
an informed consent form was signed by the owners at the screening visit.
Procedures. the study was performed over two different periods, each of 5 days, 
divided into a pretreatment phase (D0) and four days of treatment (D1-4). a wash out 
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period of 10 days was performed between the two treatments. the dogs were kept in a 
standard room with a temperature-controlled environment at 21-23 °C and exposed to an 
automatic 12-hour light/dark regimen (light phase from 7:00 AM to 7:00 PM. and a dark 
phase from 7:00 PM to 7 AM). All dogs received a normal diet given at 12:00 h each day. 
Water was available ad libitum. 
Treatments. In each period, a separate protocol was tested: protocol A consisted 
of administration of one drop of timolol 0.1% gel formulation (Timogel, 1g/1mg, 
Laboratoires Thea, Clermont-Ferrand, France) (TMG), protocol B of application of one 
drop of artificial tears (Blu Sal®, Sooft, Italy) as a placebo (PB). All treatments were 
performed by the same observer (A.P.) every 24 hours (8:00 AM) on both eyes. The 
observer was blinded to the protocol.
Measurements. The IOP and PR values were recorded in all animals five times 
daily (7:00 AM, 10:00 AM, 1:00 PM, 5:00 PM, and 9:00 PM). The IOP was recorded 
by applanation tonometry tonopen®-Vet (Medtronic, FL, USA) by the same operator 
(M.R.) after administration of a topical anesthetic (Oxybuprocaine Hydrochloride 0.4%, 
Novartis Farma, Italy). For measurements of IOP the dogs were sternally recumbent. 
During restraint, no pressure was applied to the neck.
the mean value of 5 measurements at each time point was used in the calculations. 
The mean values of the first measurement each day were considered as the baseline 
values. IOP measurements were repeated when there was an excessive deviation between 
the 5 measurements displayed by tonometry related to defects of the probe position 
or misalignment with the central portion of the cornea. the Pr was ascertained by a 
stethoscope placed by the same observer (M.P.) on the chest over the point of maximum 
heart beat intensity for 60 seconds. Adverse events (conjunctival hyperemia, discomfort, 
breathing, and allergic reaction) were recorded. 
Grading of conjunctival hyperemia was performed with a slit lamp using a standard 
scale (0-3, where: 0 is none; 1 mild; 2 moderate; and 3 severe). The presence and severity 
of hyperemia were assessed in several phase IV registration trials (D1-D4) and in both 
eyes. Allergic reactions (defined as the presence of the following symptoms: hyperemia, 
blepharospasm, swelling of the eyelid, tearing) were also graded as none, mild, moderate 
and severe.
Statistical analysis. For each dog, the IOP of both eyes and of the PR were measured. 
Data are expressed as mean and standard deviation (SD). The non-parametric approach 
was used since the numerical variables were not normally distributed, as verified by 
the Kolmogorov Smirnov test. The Friedman test (that is a non-parametric ANOVA for 
repeated-measures) was applied in order to evaluate possible significant differences in 
IOP and Pr at different times (before treatment and 1, 2, 3 and 4 days thereafter), for both 
timolol and placebo. Lastly, the Chi Square Test was used for comparisons of discrete 
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variables. Statistical analyses were performed using the SPSS for Window package 
(Version 17.0, SPSS, Inc., Chicago). P<0.05 two sides was considered to be statistically 
significant. 
Results
Intraocular pressure. During the pre-treatment phase (D0) a diurnal fluctuation of 
IOP within the normal ranges was observed (Table 2). Since no significant differences in 
IOP were detected during this time in any dogs, the baseline values were not considered 
as covariate and the statistical test was done between the treatments. the mean values of 
IOP for each day are reported in Table 2. No significant differences were detected within 
the eyes of the control group. Compared with the placebo treatment, the topical treatment 
with timolol gel formulation resulted in a significant decrease in IOP and PR (Table 1). 
The mean decrease in IOP was 3.4 mm Hg (P<0.01) in eyes treated with TMG. At 2 hours 
after the first administration, the reduction in IOP was 1.8 mm Hg in the right eye and 
1.4 mm Hg in the left. During the treatment with TMG, no significant fluctuations in IOP 
were seen. The mean SD IOPs measured on day 0 for the timolol group was 16.5 ± 1.82 
and 16.9 ± 1.59 for the protocol group. The mean SD IOPs measured on the last day of 
the treatment phase (D5) was 13.1 ± 1.3 for timolol and 17.6 ± 1.48 for the placebo group. 
On the first day of treatment, highly significant differences were observed between the 
timolol protocol and the placebo group (P<0.01). after the end of washout (10 days) IOP 
returned to pretreatment values. The maximum ocular hypotensive effect was recorded on 
day 4 for the TMG group (Table 2). The greatest mean SD reduction in IOP was detected 
at D3 of treatment in the TMG group.
table 2. Variations in IOP (mmhg) and Pr (bpm) values during the study for the protocol a 
(TMG administration) and protocol B (PB administration) during the pre-treatment phase (D0), 









od 16.1 ± 1.85 13.2 ± 2.29 13 ± 1.41 11.2 ± 0.63 13 ± 1.24 20.81 0.001
os 16.9 ± 1.79 14 ± 1.15 12.6 ± 1.57 11.2 ± 0.91 13.2 ± 1.39 27.30 0.001
IOP-PB
od 17.4 ± 0.96 17 ± 1.69 17.5 ± 1.58 16.9 ± 1.66 17.1 ± 1.37 2.41 0.660
os 16.5 ± 1.26 16.3 ± 1.25 16.5 ± 1.50 17.3 ± 1.56 18.1 ± 1.59 8.05 0.089
PR-TMG (bpm) 97 ± 6.79 76.4 ± 6.76 88.6 ± 7.02 86 ± 7.73 104 ± 7.19 32.31 0.001
PR-PB (bpm) 102 ± 7.78 93 ± 3.49 98.5 ± 5.58 98.5 ± 5.93 96.3 ± 9.33 6.39 0.171
od = oculus dexter (right eye); s = oculus sinister (left eye); 1 bpm = beats per minute
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During the treatment with the placebo, variations in IOP were observed, but they 
were not statistically significant (D1 vs D5, P = 0.37). 
Pulse rate. Since no significant differences in PR were observed during the pre-
treatment phase (D0) in any dogs, the baseline values were not considered as covariate 
and the statistical test was done between the treatments. the treatment with timolol gel 
caused a highly significant variation in PR, compared with the group control. The mean 
values of Pr for each day are reported in table 2. Compared with the placebo treatment, 
the topical treatment with timolol gel formulation resulted in a significant decrease in PR 
(Table 1). The mean decrease in PR was 10.8 (P<0.01) in the group treated with TMG. 
The mean SD PRs measured on day 0 were 976.79 for the timolol group and 1027.78 for 
the protocol (placebo?-english lector) group. the mean SD Prs measured on the second 
day of treatment phase (D5) were 76.46.76 for the timolol group and 933.49 for the 
placebo group. On the first day of treatment highly significant differences were observed 
between the timolol protocol and the placebo groups (P<0.01). after the end of washout 
(10 days) Pr was normal. 
Adverse effects. During the treatment phase, no ocular side effects or signs of 
discomfort were observed. all animals tolerated the topical medications well. table 3 
shows the trial safety results. although no severe or moderate local side effects were 
observed during and at the end of the clinical trial, TMG-treated animals had less 
conjunctival hyperemia (1/10 vs. 0/10) than patients treated with PB. 
Table 3. Local Adverse Events during day 1 (D1) and the other days (D2-D4).
TMG PB
Normal Mild Moderate Severe Normal Mild Moderate Severe
D1 Conjunctival hyperemia 9 1 0 0 0 0 0 0
D2 Conjunctival hyperemia 9 1 0 0 0 0 0 0
D3 Conjunctival hyperemia 9 1 0 0 0 0 0 0
D4 Conjunctival hyperemia 9 1 0 0 0 0 0 0
Discussion
timolol maleate is a non-selective beta-adrenergic receptor agent that reduces IOP 
by reducing the formation of aqueous humor (HOLLÓ et al., 2014). It is useful in the 
treatment of glaucoma, like other substances belonging to the same class, as it reduces 
IOP, and thus the damage to the optic nerve (SENA and LINDSLEY, 2013; LEE et al., 
2016; MEDEIROS et al., 2016; KONSTAS and HOLLÓ, 2016; LERNER et al., 2017), 
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and might protect retinal ganglion cells (VIDAL et al., 2010; SENA and LINDSLEY, 
2013). In humans, Beta-blockers are contraindicated in patients with heart failure or 
bronchial asthma for their potential adverse effects on the cardiovascular and respiratory 
systems. In veterinary medicine, any authors have observed a reduction in the pulse rate 
of normotensive and glaucomatous dogs, cats and horses treated with topical timolol at 
different concentrations, in monotherapy or associated with other drugs (PLUMMER et 
al., 2006; TAKIYAMA et al., 2006; TOFFLEMIRE et al., 2015; KILAND et al., 2016; 
MATUSOW et al., 2016). 
The purpose of this study was to evaluate the efficacy in reducing IOP in healthy dogs 
of treatment with a timolol maleate 0.1% gel formulation, as a pharmacological alternative 
in the treatment of canine glaucoma. the gel is an anion heteropolysaccaride gellan gum, 
which gels in contact with the tear fluid allowing an increase in bioavailability.
the use of the gel formulation allows application of the drug only once a day, 
facilitating therapeutic management and improving compliance by the owner.
This study showed that timolol 0.1% gel formulation administered once a day is efficient 
to reduce IOP in dogs just as in humans, but it may be the cause of pulse rate reduction. 
The administration of timolol maleate in a gel induced a significant reduction in IOP 
in the first 24 h, and this effect remained constant during the day, with hourly fluctuations 
(NUCCI et al., 2013; SEIBOLD et al., 2017). Therefore, further clinical studies in 
glaucomatous dogs are required. the period of washout between two treatments was 
considered adequate; the same study design was used in clinical trials on glaucomatous 
subjects to study the short-term activity of Beta-blockers (SCARDILLO et al., 2010). 
In our study only one dog showed mild conjunctival hyperemia after administration 
of TMG. Side effects such as local intolerance (i.e. stinging, burning), photophobia, 
ptosis blepharon conjunctivitis and superficial keratitis have been reported after ocular 
administration of Beta-Blockers in humans (ROMERO-DIAZ De LEON et al., 2016). 
In humans, the hypotensive effects of timolol gel are equivalent to those recorded 
with the formulation in a solution, applied twice daily, and with a reduction of side effects 
(KAARNINTA et al., 2016). Indeed, the gel formulation reduced systemic absorption of 
the drug, resulting in amplification of its effect and less cardiopulmonary side effects. 
In conclusion, the authors suggest that timolol maletate 0.1% gel formulation may 
potentially be used in the treatment of glaucoma in dogs, but other studies are necessary 
to evaluate the same efficacy in hypertensive dogs. 
_______
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SAŽETAK
Cilj novih lokalnih formulacija za liječenje glaukoma jest smanjiti intraokularni tlak (IOP) i nuspojave. 
Ovim su se istraživanjem željeli utvrditi učinci lokalne primjene 0,1 %-tne formulacije timolol-maleat gela 
(TMG), jedanput dnevno, na intraokularni tlak i puls (PR) u deset zdravih pasa. Jednostruko slijepo kliničko 
istraživanje obavljeno je u dva različita razdoblja. Svako je razdoblje podijeljeno u fazu predobrade (D0) i četiri 
dana obrade (D1-4) s ispiranjem od 10 dana. Obrade su se sastojale od kapanja jedne kapi 0,1 %-tne formulacije 
343Vet. arhiv 88 (3), 335-343, 2018
M. Pugliese et al.: Timolol gel formulation in dogs
timolol-gela jedanput dnevno i umjetnih suza. Vrijednosti IOP-a i PR-a utvrđene su kod svih životinja pet puta 
dnevno (7.00 h, 10.00 h, 13.00 h, 17.00 h i 21.00 h). Zabilježene su nuspojave (konjunktivalna hiperemija, 
nelagoda, disanje i alergijska reakcija). U usporedbi s placebo-obradom, topikalna terapija s formulacijom 
timolol-gela rezultirala je značajnim smanjenjem IOP-a i PR-a. Samo 24 sata nakon primjene TMG je izazvao 
značajno smanjenje IOP-a. U skupini koja je liječena TMG-om srednja vrijednost sniženja IOP-a bila je 3,4 
mmHg (P<0,01), a prosječno sniženje PR-a iznosilo je 10,8 (P<0,01). Zaključno, topikalna primjena 0,1 
%-tne formulacije timolol-maleat gela bila je učinkovita u snižavanju IOP-a u zdravih pasa. Formulacija gela 
poboljšava biološku korisnost, ali čini se da ne smanjuje kardiopulmonalne štetne učinke. 
Ključne riječi: beta-blokatori; timolol; pas; puls; intraokularni tlak
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